A phase II study of yttrium-ibritumomab (Zevalin) [ibritumomab tiuxetan Y-90] for the treatment of patients with relapsed and refractory mantle cell lymphoma.
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 16 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2009 Rituximab added as additional drug as reported by ClinicalTrials.gov.